Table 1. Clinicopathologic characteristics.
| Characteristics | Gasless | Gas | p-value | |
|---|---|---|---|---|
| Age group (yr) | 0.198 | |||
| ≤ 50 | 13 (86.7) | 30 (69.8) | ||
| > 50 | 2 (13.3) | 13 (30.2) | ||
| Smoking History | ||||
| Never | 13 (86.7) | 39 (90.7) | ||
| Past | 2 (13.3) | 2 (4.7) | 0.380 | |
| Current | 0 (0.0) | 2 (4.7) | ||
| Histology | 0.741 | |||
| In situ carcinoma | 3 (20.0) | 9 (20.9) | ||
| Invasive cancer | 10 (66.7) | 27 (62.8) | ||
| BRCA mutation | 0 (0.0) | 3 (7.0) | ||
| Interstitial mastopathy | 2 (13.3) | 4 (9.3) | ||
| Bilaterality | 0.179 | |||
| Unilateral | 11 (73.3) | 23 (53.5) | ||
| Bilateral | 4 (26.7) | 20 (46.5) | ||
| BRCA1 | 0.551 | |||
| Negative/VOUS/not tested | 15 (100.0) | 42 (97.7) | ||
| positive | 0 (0.0) | 1 (2.3) | ||
| BRCA2 | 0.127 | |||
| Negative/VOUS/not tested | 15 (100.0) | 37 (86.0) | ||
| positive | 0 (0.0) | 6 (14.0) | ||
| ER | 0.895 | |||
| Negative | 2 (15.4) | 5 (13.9) | ||
| Positive | 11 (84.6) | 31 (86.1) | ||
| PR | 0.256 | |||
| Negative | 5 (38.5) | 8 (22.2) | ||
| Positive | 8 (61.5) | 28 (77.8) | ||
| HER2 | 0.331 | |||
| Negative | 7 (53.8) | 25 (69.4) | ||
| Positive | 6 (46.2) | 11 (30.6) | ||
| Ki-67 index | 0.603 | |||
| ≤ 14% | 4 (30.8) | 14 (38.9) | ||
| > 14% | 9 (69.2) | 22 (61.1) | ||
| pT stage | 0.957 | |||
| T0 | 3 (23.1) | 8 (24.2) | ||
| T1 | 8 (61.5) | 21 (63.6) | ||
| T2 | 2 (15.4) | 4 (12.1) | ||
| pN stage | 0.016 | |||
| N0 | 9 (69.2) | 33 (97.1) | ||
| N1 | 2 (15.4) | 1 (2.9) | ||
| N2/N3 | 2 (15.4) | 0 (0.0) | ||
| Grade | 0.110 | |||
| G1 | 0 (0.0) | 8 (22.2) | ||
| G2 | 9 (69.2) | 23 (63.9) | ||
| G3 | 4 (30.8) | 5 (13.9) | ||
| Neoadjuvant CTx | 0.544 | |||
| No | 13 (100.0) | 35 (97.2) | ||
| Yes | 0 (0.0) | 1 (2.8) | ||
| Adjuvant CTx | 0.057 | |||
| No | 6 (46.2) | 27 (75.0) | ||
| Yes | 7 (53.8) | 9 (25.0) | ||
| Adjuvant RTx | 0.017 | |||
| No | 9 (69.2) | 34 (94.4) | ||
| Yes | 4 (30.8) | 2 (5.6) | ||
| Adjuvant HTx | 0.476 | |||
| No | 2 (15.4) | 9 (25.0) | ||
| Yes | 11 (84.6) | 27 (75.0) | ||
| Adjuvant TTx | 0.442 | |||
| No | 10 (76.9) | 31 (86.1) | ||
| Yes | 3 (23.1) | 5 (13.9) | ||
Values are presented as number (%).
CTx = chemotherapy; ER = estrogen receptor; HER2 = human epithelial growth factor receptor 2; HTx = hormonal therapy; PR = progesterone receptor; RTx = radiotherapy; TTx = targeted therapy; VOUS = variant of unknown significance.